Adani Power, HDFC, Tata Consumer and other stocks to watch out for on May 7

May 7, 2021

By: Rounak Jain

Adani Power

It reported consolidated profit of ₹13 crore in the March 2021 quarter against a loss of ₹1,313 crore a year ago, while revenue rose 3 percent to ₹6,374 crore.

Credit: Adani-Power

HDFC

It is all set to declare its March 2021 quarter results today.

Credit: HDFC

Tata Consumer

It reported consolidated net profit of ₹54 crore in the March 2021 quarter against a loss of ₹76 crore a year ago. Revenue increased by 26 percent to ₹3,037 crore.

Credit: Tata-Consumer

Earnings today

HDFC, UltraTech Cement, Dabur India, Cholamandalam Investment and Finance Company, Kansai Nerolac Paints, Pioneer Distilleries, Reliance Home Finance, Reliance Power

Credit: Pixabay

Hero MotoCorp

Its standalone net profit for the March 2021 quarter jumped 39 percent to ₹865 crore while revenue also increased by 39 percent to ₹8,686 crore, year-on-year. Volume grew by 19 percent.

Credit: Hero-MotoCorp

Adani Transmission

Its consolidated net profit for the March 2021 quarter jumped by 153 percent to ₹238 crore. Revenue fell by 14 percent to ₹2,726 crore, year-on-year.

Credit: Adani-Transmission

SBI Life Insurance

US-based equity firm Carlyle will sell up to 3.5 percent of its stake in the company at ₹945 per share via a block deal.

Credit: SBI-Life-Insurance

Zensar Technologies

It has been selected to develop UK-based FinTech Infinity Circle’s wealth management platform.

Credit: Zensar-Technologies

Raymond

It reported a net profit of ₹58 crore in the March 2021 quarter against a net loss of ₹69 crore a year ago. Revenue increased 9 percent to ₹1,407 crore.

Credit: Wikimedia

Blue Star

It reported a sharp jump in net profit to ₹68 crore in the March 2021 quarter from ₹9 crore a year ago. Revenue surged by 24 percent to ₹1,612 crore.

Credit: Blue-Star

More than 350 Indonesian healthcare workers vaccinated with China's Sinovac vaccine got COVID-19 and dozens are hospitalized, raising questions about the vaccine's efficacy on variants